Pfizer and BioNTech have begun a clinical trial for their Omicron-specific COVID-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, ...

Pfizer Inc. and BioNTech SE have announced that initial lab studies show a third dose of their Covid-19 vaccine neutralizes the Omicron variant. These results come as great news amid fears of a new ...

Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, ...

NEW YORK (WABC) -- We're learning more about the FDA's decision to further delay the COVID-19 vaccine that Pfizer is testing for children under age 5. This youngest group is the only age group not yet ...

Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...

Pfizer and BioNTech said Tuesday they've begun clinical trials for an omicron-based COVID-19 vaccine. According to a press release, the vaccine will be tested initially in adults aged 18 to 55. "While ...

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA ...

If COVID-19 booster shots become an annual precaution, the same way we get a flu shot every year, the next one may be formulated differently. Moderna and Pfizer working on a bivalent vaccine that ...

Pfizer’s booster provides a much stronger immune response against the omicron variant than its two-shot series, according to the results of two recent studies. The University of Oxford released ...

Pfizer CEO Albert Bourla said Monday he expects the company's Covid-19 treatment pill to be effective against the omicron variant of the virus causes Covid-19. "The good news when it comes to our ...